French
German
Italian
Medical need: Refractory Angina
- Long-lasting symptoms (for > 3months)
- Established reversible ischemia
- Coronary artery disease which cannot be controlled by a combination of escalating medical therapy (2° or 3° line agents), CAGB or PCI (including CTO)
- 30-50.000 new cases in Europe
- 5% of Coronary Artery Disease (CAD) patients
- are no longer suitable for conventional treatments
- Poor health status and impaired quality of life (Canadian Cardiovascular Society [CCS] functional class III or IV)
- Causes long-term medication, disability and repeated coronary investigations: In the EU 18.8 billion/year is the estimated total healthcare cost related to coronary heart disease (CHD).
- No curative therapies available
CPCPlus therapy is designed to be a novel, cost-effective cardiac ATMP delivered directly to the ischaemic heart through specific catheters. The product exerts a potent angiogenic effect in the ischaemic myocardium. From a clinical perspective, the technology aims to address the treatment gap for patients suffering from refractory angina, a heart condition that is not reversible due to insufficient oxygen supply to the myocardium.
References:
The problem of chronic refractory angina. Report from the ESC Joint Study Group on the Treatment of Refractory Angina
https://academic.oup.com/eurheartj/article/23/5/355/554602#google_vignette